Orchestra BioMed Holdings has announced that FDA has approved its Investigational Device Exemption amendment to initiate an updated design of the Company’s planned Virtue SAB in the Treatment of Coronary ISR Trial.
Amerikooler highlights its XPS Insulation, engineered to deliver "unparalleled" thermal performance, durability, and environmental responsibility across a wide range of applications.
Sail Biomedicines’ Kerry Benenato and Rajesh Ramaswamy discuss the roles artificial intelligence (AI) can play in informing programmability, using the example of Sail’s tailored Endless RNATM (eRNATM) medicines.
The Novo Nordisk Foundation has announced the latest edition of its annual Challenge Programme, where for the first time it is inviting researchers from outside Denmark, in the European Schengen area, Ireland and the UK.
Metrion Biosciences, a preclinical contract research organisation (CRO), has announced the launch of its validated, high-throughput NaV1.9 screening assay to advance discovery and development of novel pain therapeutics.
Thermo Fisher Scientific is employing an enhanced platform technology and a new CHO K-1 cell line that can reduce timelines to Investigational New Drug (IND) filing from 13 to nine months.
Ramesh Jagadeesan, vice president, head of analytical services at Recipharm shares his insights on the role of analytical services in drug development.
Ferrer, a pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V., a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement.
PCI Pharma Services – a global contract development and manufacturing organisation (CDMO) focused on innovative biopharma therapies – is acquiring an entire equity stake in Ajinomoto Althea.
After purchasing Veolia Water Technologies’ new ORION 2000S RO and CEDI unit, a major manufacturer has been able to expand its production capacity and reduce its water footprint by up to 40%.
Considering the overlapping needs of a drug therapy delivered via wearable injectors, each project benefits from its own specific approach. Portescap’s business development manager for medical applications, Dave Beckstoffer, explains.
